lobbying_activities: 1119225

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1119225	56bb2b4c-5770-4f00-baae-29f51d17af19	Q2	THE PETRIZZO GROUP, INC.	305932	FATE THERAPEUTICS, INC.	2011	second_quarter	MED	Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine to restore hearing by using the fundemental biological mechanisms that guide cell fate to develop innovative therapeutics. Fate's research and drug development focuses on modulating adult stem cell biology to treat disease and improve health.	Defense Advanced Research Projects Agency (DARPA),HOUSE OF REPRESENTATIVES,SENATE	20000		0	0	2011-07-18T20:12:18.380000-04:00